Recent changes to FDA-approved labeling.
D000081:Acetamides / Q000627:therapeutic use; D000634:Aminoquinolines / Q000627:therapeutic use; D000069446:Atazanavir Sulfate; D000069059:Atorvastatin; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D004304:Dosage Forms; D004348:Drug Labeling / Q000331:legislation & jurisprudence* / Q000379:methods / Q000639:trends*; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000627:therapeutic use; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D000077271:Imiquimod; D007328:Insulin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D061268:Insulin Lispro; D008333:Mandelic Acids / Q000627:therapeutic use; D009842:Oligopeptides / Q000627:therapeutic use; D053139:Oseltamivir; D011725:Pyridines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D011994:Recombinant Proteins; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
D000081:Acetamides; D000634:Aminoquinolines; D004304:Dosage Forms; D006538:Heptanoic Acids; D007328:Insulin; D061268:Insulin Lispro; D008333:Mandelic Acids; D009842:Oligopeptides; D011725:Pyridines; D011758:Pyrroles; D011994:Recombinant Proteins; D004921:Erythropoietin; D053139:Oseltamivir; D000069446:Atazanavir Sulfate; D000068817:Epoetin Alfa; D000069059:Atorvastatin; D019274:Botulinum Toxins, Type A; C005419:oxybutynin; D000077271:Imiquimod